Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Quest Partners LLC

Quest Partners LLC increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 898.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,434 shares of the company’s stock after purchasing an additional 3,090 shares during the period. Quest Partners LLC’s holdings in Dyne Therapeutics were worth $123,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DYN. KBC Group NV increased its stake in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of Dyne Therapeutics by 4.3% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 40,091 shares of the company’s stock valued at $1,440,000 after buying an additional 1,636 shares during the period. Victory Capital Management Inc. grew its position in shares of Dyne Therapeutics by 59.4% during the 3rd quarter. Victory Capital Management Inc. now owns 30,537 shares of the company’s stock valued at $1,097,000 after buying an additional 11,385 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in Dyne Therapeutics during the third quarter worth about $1,588,000. Finally, Privium Fund Management B.V. lifted its holdings in Dyne Therapeutics by 7.1% in the third quarter. Privium Fund Management B.V. now owns 15,016 shares of the company’s stock worth $539,000 after acquiring an additional 1,000 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $31.13 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $10.12 and a 12 month high of $47.45. The firm has a market capitalization of $3.17 billion, a PE ratio of -8.74 and a beta of 1.10. The company’s 50 day simple moving average is $31.89 and its 200 day simple moving average is $35.39.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the transaction, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders have sold a total of 176,257 shares of company stock valued at $6,193,718 over the last three months. Company insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DYN shares. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. Royal Bank of Canada began coverage on Dyne Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $45.00 target price on the stock. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Oppenheimer reissued an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.82.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.